Business Context and Reporting Period
Company: Ginkgo Bioworks Holdings, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: September 4, 2025
Event: Entry into a Material Definitive Agreement (Sales Agreement).
Key Financial Metrics
This filing does not report specific revenue, profit, cash flow, or margin figures for a completed period. The primary financial metric disclosed is the potential capital raise:
- Maximum Offering Size: Up to $100,000,000 in Class A common stock.
- Commission: Up to 3.0% of gross proceeds payable to the sales agent.
- Use of Proceeds: General corporate purposes, including operations, technology development, working capital, and capital expenditures.
Material Changes
On September 4, 2025, the Company entered into a Sales Agreement with Allen & Company LLC. This agreement establishes an "at-the-market" (ATM) equity offering program. The Company may sell shares through the agent under an effective Registration Statement on Form S-3 (filed August 7, 2025). No shares have been sold as of the filing date; the agreement provides the option to sell up to the aggregate limit.
Guidance, Outlook, and Risks
Management Commentary: The Company anticipates using net proceeds for general corporate purposes but explicitly states it cannot provide assurances that it will issue any shares under the agreement.
Risks and Contingencies: The filing highlights several forward-looking risks, including:
- Potential dilution of existing shareholders and adverse impact on market price.
- Uncertainty regarding the ability to raise additional capital in the future.
- Intense competition in the synthetic biology industry and rapidly changing technology.
- Reliance on customers to develop and manufacture products using the Company's engineered cells.
- Regulatory compliance and global economic factors.
Investor Verification Checklist
- Verify the current market price of Class A common stock (DNA) to assess potential dilution impact.
- Review the Company's most recent Form 10-Q or 10-K for actual cash burn rates and liquidity position.
- Monitor subsequent filings to determine if and when shares are actually sold under the ATM program.
- Check for any updates to the "Risk Factors" section in the 2024 Annual Report referenced in the filing.